Xalud Therapeutics

About:

Xalud Therapeutics is a biotech company that develops therapies for the treatment of neuro-inflammatory diseases.

Twitter/X: xaludtx

Top Investors: PBM Capital Group

Description:

Xalud Therapeutics is a biotech company that develops therapies for the treatment of neuro-inflammatory diseases. It offers a gene therapy platform that addresses chronic pain. The lead product candidate, XT-150 is in two P2 clinical studies for the treatment of Osteoarthritis Pain. Xalud is a portfolio company of PBM Capital Group. The company was established in 2009 and is based in San Francisco, California, United States.

Total Funding Amount:

$42.3M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

New York, New York, United States

Founded Date:

2009-01-01

Founders:

Linda Watkins, Peter Heinecke

Number of Employees:

11-50

Last Funding Date:

2021-08-24

IPO Status:

Private

Industries: